Spyre Therapeutics Net Profit Margin Growth & History (SYRE)
Spyre Therapeutics's net profit margin was −38,238.15% for fiscal 2023.
View full Spyre Therapeutics company overviewSpyre Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −38,238.15% | −34639.39 pp |
| 2022 | 2022-12-31 | −3,598.75% | −3247.61 pp |
| 2021 | 2021-12-31 | −351.14% | — |
| 2018 | 2018-12-31 | −1,140.64% | −617.37 pp |
| 2017 | 2017-12-31 | −523.27% | −54.42 pp |
| 2016 | 2016-12-31 | −468.84% | — |
Spyre Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2023 | 2023-06-30 | −31,552.47% | −27980.79 pp |
| Q1 2023 | 2023-03-31 | −9,304.04% | −7509.91 pp |
| Q4 2022 | 2022-12-31 | −11,203.57% | −10642.48 pp |
| Q3 2022 | 2022-09-30 | −10,479.31% | −9027.77 pp |
| Q2 2022 | 2022-06-30 | −3,571.68% | −3521.81 pp |
| Q1 2022 | 2022-03-31 | −1,794.13% | — |
| Q4 2021 | 2021-12-31 | −561.09% | — |
| Q3 2021 | 2021-09-30 | −1,451.54% | — |
| Q2 2021 | 2021-06-30 | −49.87% | — |
| Q2 2018 | 2018-06-30 | −395.88% | +52.53 pp |
| Q1 2018 | 2018-03-31 | −537.68% | +98.47 pp |
| Q4 2017 | 2017-12-31 | −437.15% | — |
| Q3 2017 | 2017-09-30 | −624.43% | — |
| Q2 2017 | 2017-06-30 | −448.41% | — |
| Q1 2017 | 2017-03-31 | −636.15% | — |
Spyre Therapeutics net profit margin trends
Over the last five fiscal years, Spyre Therapeutics's net profit margin decreased from −1,140.64% to −38,238.15%, a change of −37097.51 percentage points. The latest reported quarter, Q2 2023, shows −31,552.47%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spyre Therapeutics source filings ↗